{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:01:46Z","timestamp":1792440106524,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coviro.2019.07.003","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:38:31Z","timestamp":1565285911000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Antibody therapy for Lassa fever"],"prefix":"10.1016","volume":"37","author":[{"given":"Robert W","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M","family":"Hastie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad E","family":"Mire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Branco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Ollmann Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Garry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.07.003_sbref0005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4269\/ajtmh.1970.19.670","article-title":"Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings","volume":"19","author":"Frame","year":"1970","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0010","doi-asserted-by":"crossref","first-page":"695","DOI":"10.4269\/ajtmh.1970.19.695","article-title":"An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report","volume":"19","author":"Troup","year":"1970","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0035-9203(72)90271-4","article-title":"Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria","volume":"66","author":"Carey","year":"1972","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0020","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4269\/ajtmh.1970.19.680","article-title":"Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus","volume":"19","author":"Buckley","year":"1970","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0025","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/227174a0","article-title":"Isolation and antigenic characterization of Lassa virus","volume":"227","author":"Buckley","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.003_bib0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(12)61871-6","article-title":"Lily Lyman Pinneo","volume":"380","author":"Watts","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.003_bib0035","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4269\/ajtmh.12-0466","article-title":"A historical look at the first reported cases of Lassa fever: IgG Antibodies 40 years after acute infection","volume":"88","author":"Bond","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0040","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical sequencing uncovers origins and evolution of Lassa virus","volume":"162","author":"Andersen","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0050","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.1.6073.1399","article-title":"Lassa fever in Panguma Hospital, Sierra Leone, 1973-6","volume":"1","author":"Keane","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.coviro.2019.07.003_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/15303660160025903","article-title":"Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations","volume":"1","author":"Bausch","year":"2001","journal-title":"Vector Borne Zoonotic Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0065","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4269\/ajtmh.1974.23.1131","article-title":"Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies","volume":"23","author":"Fraser","year":"1974","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0070","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4269\/ajtmh.1973.22.780","article-title":"Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972","volume":"22","author":"Mertens","year":"1973","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4269\/ajtmh.1973.22.773","article-title":"A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972","volume":"22","author":"Monath","year":"1973","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3201\/eid1607.100146","article-title":"Detection of Lassa virus, Mali","volume":"16","author":"Safronetz","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0085","first-page":"47","article-title":"Characterization of contacts of the population of Guinea with synanthropic rodents as Lassa fever virus carriers","year":"2007","journal-title":"Med Parazitol (Mosk)"},{"key":"10.1016\/j.coviro.2019.07.003_bib0090","first-page":"389","article-title":"Clinical observations in 42 patients with Lassa fever","volume":"31","author":"Knobloch","year":"1980","journal-title":"Tropenmed Parasitol"},{"key":"10.1016\/j.coviro.2019.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Richmond","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.coviro.2019.07.003_bib0100","first-page":"75","article-title":"Lassa fever","volume":"262","author":"McCormick","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"Suppl. 4","key":"10.1016\/j.coviro.2019.07.003_bib0105","doi-asserted-by":"crossref","first-page":"S743","DOI":"10.1093\/clinids\/11.Supplement_4.S743","article-title":"Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted","volume":"11","author":"Peters","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0110","article-title":"Increase in Lassa fever cases in Nigeria, January-March 2018","volume":"25","author":"Ilori","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0115","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study","volume":"18","author":"Okokhere","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002748","article-title":"Lassa fever in post-conflict Sierra Leone","volume":"8","author":"Shaffer","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0125","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.coviro.2019.07.003_bib0130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/infdis\/jit004","article-title":"A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in Cynomolgus macaques","volume":"207","author":"Safronetz","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0135","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3201\/eid2403.171905","article-title":"New lineage of Lassa Virus, Togo, 2016","volume":"24","author":"Whitmer","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(79)90790-6","article-title":"Experimental Lassa fever virus infection successfully treated with ribavirin","volume":"1","author":"Stephen","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.003_bib0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0041-008X(82)90334-9","article-title":"Preclinical evaluation of monkeys of a ribavirin regimen proposed for use in Lassa fever patients","volume":"64","author":"Wannarka","year":"1982","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.coviro.2019.07.003_bib0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","article-title":"Evaluation of Lassa antiviral compound ST-193 in a guinea pig model","volume":"90","author":"Cashman","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.07.003_bib0165","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3201\/eid1612.100994","article-title":"Ribavirin for Lassa fever postexposure prophylaxis","volume":"16","author":"Hadi","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0166-3542(92)90073-E","article-title":"Unexpected adverse reactions during a clinical trial in rural west Africa","volume":"19","author":"Fisher-Hoch","year":"1992","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.07.003_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007439","article-title":"A potent Lassa virus antiviral targets an arenavirus virulence determinant","volume":"14","author":"Madu","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.003_bib0180","doi-asserted-by":"crossref","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2019.07.003_bib0185","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3201\/eid2409.180233","article-title":"Use of Favipiravir to treat Lassa virus infection in Macaques","volume":"24","author":"Rosenke","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0190","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and Ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02134-18","article-title":"Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans","volume":"93","author":"Christensen","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.003_bib0200","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1016\/j.celrep.2018.11.067","article-title":"Cryo-EM structures of eastern equine encephalitis virus reveal mechanisms of virus disassembly and antibody neutralization","volume":"25","author":"Hasan","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2019.07.003_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.003_bib0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005418","article-title":"Acidic pH-induced conformations and LAMP1 binding of the lassa virus glycoprotein spike","volume":"12","author":"Li","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.003_bib0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/v4010083","article-title":"The curious case of arenavirus entry, and its inhibition","volume":"4","author":"Nunberg","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2019.07.003_bib0220","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.86.1.317","article-title":"Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene","volume":"86","author":"Fisher-Hoch","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2019.07.003_bib0225","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/1743-422X-8-478","article-title":"Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection","volume":"8","author":"Branco","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.07.003_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/jcm.20.2.239-244.1984","article-title":"Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay","volume":"20","author":"Niklasson","year":"1984","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.coviro.2019.07.003_bib0235","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/iai.44.2.528-533.1984","article-title":"Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain","volume":"44","author":"Jahrling","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.coviro.2019.07.003_bib0240","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/149.3.420","article-title":"Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys","volume":"149","author":"Jahrling","year":"1984","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0245","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","article-title":"Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization","volume":"79","author":"Jahrling","year":"1985","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.003_bib0250","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2007.10.010","article-title":"Treatment of Argentine hemorrhagic fever","volume":"78","author":"Enria","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.07.003_bib0255","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF02122443","article-title":"Current status of the treatment of Argentine hemorrhagic fever","volume":"175","author":"Enria","year":"1986","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0260","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","article-title":"Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma","volume":"2","author":"Enria","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.003_bib0265","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/514211","article-title":"Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group","volume":"177","author":"Maiztegui","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0270","article-title":"Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0275","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","article-title":"Monoclonal antibodies for emerging infectious diseases \u2013 borrowing from history","volume":"378","author":"Marston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0280","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41591-018-0315-0","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"25","author":"Kisalu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0290","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1086\/423213","article-title":"Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants","volume":"190","author":"DeVincenzo","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0295","first-page":"637","article-title":"Multidrug Ebola trial underway in democratic republic of Congo","volume":"321","author":"Friedrich","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.coviro.2019.07.003_bib0300","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1016\/j.celrep.2018.12.001","article-title":"A protective monoclonal antibody targets a site of vulnerability on the surface of rift valley Fever virus","volume":"25","author":"Allen","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2019.07.003_bib0305","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.str.2017.11.017","article-title":"Structural and functional characterization of a cross-reactive dengue virus neutralizing antibody that recognizes a cryptic epitope","volume":"26","author":"Li","year":"2018","journal-title":"Structure"},{"key":"10.1016\/j.coviro.2019.07.003_bib0310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiy532","article-title":"Structural characterization of Pan-ebolavirus antibody 6D6 Targeting the fusion peptide of the surface glycoprotein","volume":"219","author":"Milligan","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0315","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2019.07.003_bib0320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1743-422X-3-41","article-title":"The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C","volume":"3","author":"Eichler","year":"2006","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0325","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2019.07.003_sbref0330","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2019.07.003_bib0335","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.003_bib0340","series-title":"List of Blueprint Priority Diseases","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.coviro.2019.07.003_bib0345","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(17)30062-2","article-title":"CEPI: preparing for the worst","volume":"17","author":"Burki","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.003_bib0350","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1073\/pnas.1803990115","article-title":"Structure of the Lassa virus glycan shield provides a model for immunological resistance","volume":"115","author":"Watanabe","year":"2018","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:03:16Z","timestamp":1761818596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":70,"alternative-id":["S1879625719300367"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.003","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody therapy for Lassa fever","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}